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ABSTRACT 
Objective: Neuroinflammation is the inflammation of brain and brain tissue. Activation of glial cells (Microgila and astrocytes) takes place during 
neuroinflammation due to which a number of inflammatory mediators are released in brain. Thus the objective of the current study is to evaluate 
the potentialanti-neuroinflammatory activity of various phytoconstituents through virtual binding interactions against inflammatory mediators.  
Methods: The preliminary screening of phytoconstituents was done by Lipinski’s rule of five. Inflammatory mediators; Cycooxygenase-1 (COX-1), 
Cyclooxygenase-2 (COX-2), Tumor necrosis factor-α (TNF-α), Interleukin 1-β (IL-1β), inducible nitric oxide synthase (iNOS) and neuronal nitric oxide 
synthase (nNOS) protein sequence was retrieved from STRING database and molecular modeling was performed through SWISS-MODEL. And ligands ID 
was retrieved from ZINC database, and their MOL2 format was downloaded for further processing. Docking study of phytoconstituents with ligands was 
performed by iGEMDOCK. By using ADMET; absorption, distribution, metabolism, excretion and toxicity properties were predicted. 
Results: Sissotrin out of the various phytoconstituents is the most active component having high binding affinity and inhibitor of neuroinflammatory activity. 
Conclusion: Sissotrin may be a good inhibitor for neuroinflammatory disorders and act as anti-neuro inflammatory agent. 
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INTRODUCTION 
Inflammation is a protective reaction to various tissue injuries, in 
which debris or damaged tissue is removed and in turn, healing the 
affected part. When the inflammatory process becomes worse and 
tissue damage enhanced and more widespread, it is called chronic 
inflammation. In brain inflammation, there is excessive production of 
Reactive oxygen species (ROS) by mitochondria and NADPH oxidase 
(NOX), which leads to tissue injury, brain inflammation and 
neurodegenerative diseases like Alzheimer’s disease (AD) and 
Parkinson’s disease (PD). In addition, there are various inflammatory 
mediators involved in it, such as COX-2, cytosolic phospholipase A2 
(cPLA2), iNOS and cytokines. Glial cells, which include microglia and 
astrocytes, play a key role in the neuroinflammatory process. 
Activation of glial cells leads to neuroinflammation [1-4].  
Need to screen natural inhibitors 
Phytoconstituents are natural plant-derived products that have been 
part of traditional medicine, since ancient time and have contributed 
towards drug discovery or development. However, with time, it has 
also become more advanced and technically complicated. Number of 
advanced approaches is available for drug development, and 
bioinformatics is one of the important aspect of drug development. 
It is helpful in biotechnology for searching lead compounds as plant 
derived phytoconstituents are the major source of drugs used in the 
treatment of various diseases [4, 5]. Advancement in the tools of 
bioinformatics has made possible to conduct in-silico studies leading 
to drug development and discovery, thus saving significant time and 
resources. Therefore, the aim of present study is to reveal the 
therapeutic potential of various phytoconstituents to demonstrate 
their anti-neuro inflammatory activity.  
Synthetic anti-neuro inflammatory drugs effectively suppress the 
diseases or any type of disorders in a short time, but the synthetic 
drugs are costly and result in side effects which are relatively safer 
in plant-derived natural drugs. Natural compounds also have some 
side effects; therefore, to overcome this limitation, computer aided 
drug design approach is a valuable method to investigate the targets 
and the effect of natural products [6, 7].  
MATERIALS AND METHODS 
A. Target protein identification 
The protein sequence of target genes was retrieved from string 
database and modeling of it through SWISS-MODEL and taken for 
docking. The models were validated through procheck program. 
B. Ligands preparation 
Ligand ID was retrieved from ZINC database, and its MOL2 format 
was downloaded for docking. 
 
Fig. 1: Experimental approach for putative drug discovery 
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The molecular docking of 14 phytoconstituents was carried out 
using iGEMDOCK software with all the target proteins (COX-1, COX-
2, IL-1β, iNOS, nNOS and TNF-α).  
The binding site of the target protein was outfitted and compounds 
were imported for docking. The ligand molecule shows lowest 
binding affinity with the target protein is the best inhibitor to be 
chosen as a future drug [8, 9]. 
Drug likeliness 
The ADMET parameters were determined by Admet SAR (Admet 
structure-activity relationship). These properties are valuable for a 
drug to be eligible for drug likeliness. Admet SAR supports the most 
recent data for various compounds allied with known ADMET 
profiles. The database has 22 qualitative categorization and 5 
quantitative waning models with high analysis for estimation of 
mammalian ADMET properties of novel compounds [9]. 
 
Table 1: Bioactive components of various plants obtained from data mining (1-14) 
S. No. Zn file Compound name 
1. Zinc_04096693 Sissotrin 
2. Zinc_03872446 Ellagic Acid 
3. Zinc_03869685 Quercitin 
4. Zinc_18847037 Biochanin A 
5. Zinc_18825330 Genistein 
6. Zinc_18847034 Daidzein 
7. zinc_8681784 Beta-sitosterol 
8. Zinc_00001504 Gallic acid 
9. Zinc-03802189 Linolenic acid 
10. Zinc_00153654 Sinapic acid 
11. Zinc_00021790 Ethyl gallate 
12. Zinc_14438802 Ascorbic acid 
13. Zinc_00083315 Tryptophan 
14. Zinc_02557133 Sulforaphane 
 
Table 2: Bioactive components with their structure (1-14) 
S. No. Zn file Compound name Structure 
1. Zinc_04096693 Sissotrin 
 
2. Zinc_03872446 Ellagic Acid 
 
3. Zinc_03869685 Quercitin 
 
4. Zinc_18847037 Biochanin A 
 
5. Zinc_18825330 Genistein 
 
6. Zinc_18847034 Daidzein 
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7. Zinc_8681784 Beta-sitosterol 
 
8. Zinc_00001504 Gallic acid 
 
9. Zinc-03802189 Linolenic acid 
 
10. Zinc_00153654 Sinapic acid 
 
11. Zinc_00021790 Ethyl gallate 
 
12. Zinc_14438802 Ascorbic acid 
 
13. Zinc_00083315 Tryptophan 
 
14. Zinc_02557133 Sulforaphane 
 
 
Table 3: Interaction profiles of phytoconstituents with COX-1 
S. No. Zn file Compound name Energy(kcal/mol) VDW H-Bond Elec 
1. Zinc_04096693 Sissotrin -143.2 -118.54 -24.68 0 
2. Zinc_03872446 Ellagic Acid -111.6 -82.69 -28.9 0 
3. Zinc_03869685 Quercitin -111.94 -82.29 -29.65 0 
4. Zinc_18847037 Biochanin A -113.1 -102.18 -10.89 0 
5. Zinc_18825330 Genistein -120.7 -103.92 -16.75 0 
6. Zinc_18847034 Daidzein -112.1 -98.74 -13.4 0 
7. zinc_8681784 Beta-sitosterol -100.4 -93.4 -7 0 
8. Zinc_27643987 Indomethacine(Control) -119 -109.95 -9.01 0 
9. Zinc_00001504 Gallic acid -76.2 -62.02 -14.23 0 
10. Zinc-03802189 Linolenic acid -118.8 -102.98 -12.23 -3.62 
11. Zinc_00153654 Sinapic acid -91.9 -80.77 -9.99 -1.09 
12. Zinc_00021790 Ethyl gallate -91.9 -59.32 -32.58 0 
13. Zinc_14438802 Ascorbic acid -80.5 -37.2 -43.33 0 
14. Zinc_00083315 Tryptophan -88.9 -69.29 -19.5 -0.1 
15. Zinc_02557133 Sulforaphane -67.6 -58.67 -8.9 0 
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RESULTS AND DISCUSSION 
Molecular docking simulation 
Docking of 14 phytoconstituents with COX-1 
The binding energy of sissotrin out of all 14 compounds is lowest 
i.e.-143.2, and it is also lower than the control drug, Indomethacin (-
119). The interaction profile of other compounds also has lower 
energy than control drug, as shown in table 3. It shows that sissotrin 
is a good inhibitor of COX-1 as compared to control drug. 
Docking of 14 phytoconstituents with COX-2 
The binding energy of sissotrin out of all 14 compounds, is lowest 
i.e.-129.4, while Meloxicam has-96.7, which is a controlled drug.  
The interaction profile shows other compounds also have lower 
energy than the control drug, as shown in table 4. Lower energy than 
the drug control shows along with other compounds sissotrin could 
be putative inhibitors of COX-2. 
Docking of 14 phytoconstituents with IL-1β 
The binding energy of sissotrin out of all 14 compounds is lowest 
i.e.-109, and control drug Lidocaine shows binding energy of-69.8. 
The interaction profile and energies of other compounds also have 
lower energy than control drug, as shown in table 5. Interacting 
properties of the compounds shows that sissotrin is a potent 
inhibitor of IL-1β, along with other compounds that shows lower 
energies compared to Meloxicam. 
 
Table 4: Interaction profiles of phytoconstituents with COX-2 
S. No. Zn file Compound name Energy(kcal/mol) VDW H-Bond Elec 
1. Zinc_04096693 Sissortin -129.4 -105.09 -24.29 0 
2. Zinc_03872446 Ellagic Acid -118.5 -78.67 -39.87 0 
3. Zinc_03869685 Quercitin -117.7 -92.76 -24.97 0 
4. Zinc_18847037 Biochanin A -108.5 -93.25 -39.58 0 
5. Zinc_18825330 Genistein -107 -89.98 -17.04 0 
6. Zinc_18847034 Daidzein -103.6 -91.51 -12.06 0 
7. zinc_8681784 Beta-sitosterol -100.1 -100.14  0 0 
8. Zinc_13129998 Meloxicam(Control) -96.7 -78.92 -17.82 0 
9. Zinc_00001504 Gallic acid -92.7 -65.73 -26.98 0 
10. Zinc-0302189 Linolenic acid -88.8 -76.72 -12.06 0 
11. Zinc_00153654 Sinapic acid -88 -73.2 -9.91 -4.95 
12. Zinc_00021790 Ethyl gallate -84.6 -54.01 -30.57 0 
13. Zinc_14438802 Ascorbic acid -83.06 -43.48 -39.58 0 
14. Zinc_00083315 Tryptophan -81.7 -71.41 -10.28 0 
15. Zinc_02557133 Sulforaphane -68.4 -58.75 -9.61 0 
 
Table 5: Interaction profiles of phytoconstituents with IL-1β 
S. No. Zn file Compound name Energy(kcal/mol) VDW H-Bond Elec 
1. Zinc_04096693 Sissortin -109 -74.71 -34.32 0 
2. Zinc_03869685 Quercitin -100.3 -79.97 -20.32 0 
3. Zinc_03872446 Ellagic Acid -99.7 -74.16 -25.51 0 
4. Zinc_18825330 Genistein -90.9 -68.37 -22.52 0 
5. Zinc_00083315 Tryptophan -89.4 -62.78 -25.93 -0.72 
6. Zinc_18847034 Daidzein -87.8 -75.75 -12.04 0 
7. Zinc-03802189 Linolenic acid -82.8 -75.93 -6.9 0 
8. Zinc_8681784 Beta-sitosterol -80 -75.46 -4.57 0 
9. Zinc_14438802 Ascorbic acid -78.5 -42.66 -35.82 0 
10. Zinc_18847037 Biochanin A -78.1 -66.17 -11.97 0 
11. Zinc_00021790 Ethyl gallate -76.9 -56.94 -20 0 
12. Zinc_00153654 Sinapic acid -72.8 -58.69 -14.08 0 
13. Zinc_00001504 Gallic acid -71.9 -56.52 -15.41 0 
14. Zinc_00020237 Lidocaine(Control) -69.8 -66.29 -3.5 0 
15. Zinc_02557133 Sulforaphane -62.2 -49.27 -12.97 0 
 
Table 6: Interaction profiles of phytoconstituents with iNOS 
S. No. Zn file Compound name Energy(kcal/mol) VDW H-Bond Elec 
1. Zinc_04096693 Sissortin -133.16 -110.74 -22.42 0 
2. Zinc_18847037 Biochanin A -123.1 -109.9 -13.15 0 
3. Zinc_18847034 Daidzein -109.1 -100.09 -9.02 0 
4. Zinc_03872446 Ellagic Acid -103.2 -93.58 -9.59 0 
5. Zinc_03869685 Quercitin -100.6 -87.6 -13.03 0 
6. Zinc_18825330 Genistein -98.4 -71.26 -27.15 0 
7. Zinc_00021790 Ethyl gallate -93.3 -60.21 -33.08 0 
8. Zinc_08143636 Tomatidine(Control) -90.4 -80.65 -9.73 0 
9. Zinc_00001504 Gallic acid -90.2 -52.16 -35.33 -2.69 
10. Zinc_8681784 Beta-sitosterol -89.7 -87.94 -1.76 0 
11. Zinc-03802189 Linolenic acid -88.9 -68.98 -20.52 -0.57 
12. Zinc_00153654 Sinapic acid -88.8 -84.4 -4.42 0 
13. Zinc_00083315 Tryptophan -86.7 -86.7  0 0 
14. Zinc_14438802 Ascorbic acid -85.4 -46.07 -39.29 0 
15. Zinc_02557133 Sulforaphane -63.4 -50.86 -12.5 0 
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Docking of 14 phytoconstituents with iNOS 
The binding energy of sissotrin out of all 14 compounds is lowest 
i.e.-133.16, and drug control tomatidine shows binding energy of-
90.4. The interaction profile of other compounds also has lower 
energy than the control drug, as shown in table 6, demonstrating 
that sissotrin is the best candidate among the putative inhibitors. 
Docking of 14 phytoconstituents with nNOS 
The binding energy of sissotrin out of all 14 compounds is lowest 
i.e.-120.1, and drug control L-NAME shows binding energy of-96. 
The interaction profile of the phytol compounds (table 7) 
demonstrates that sissotrin is a best putative inhibitor of nNOS 
among all the listed compounds. 
Docking of 14 phytoconstituents with TNF-α 
The binding energy of sissotrin out of all 14 compounds is lowest 
i.e.-100.8, and control drug Apremilast shows binding energy of-
91.1. The interaction profile of other compounds also has lower 
energy than the control drug (table 8). Profile of the phyto-
compounds shows that sissotrin is a preferably good inhibitor of 
TNF-α as compared to the control drug. 
ADMET profile 
AdmetSAR predicts that phytoconstituents have drug-like properties. 
All phytoconstituents showed ADMET properties in the acceptable 
range (table 9.1, 9.2, 9.3) 
 
Table 7: Interaction profiles of phytoconstituents with nNOS 
S. No. Zn file Compound name Energy(kcal/mol) VDW H-Bond Elec 
1. Zinc_04096693 Sissortin -120.1 -92.29 -27.78 0 
2. Zinc_03869685 Quercitin -102.4 -78.41 -23.94 0 
3. Zinc_03872446 Ellagic Acid -101.5 -75.41 -26.06 0 
4. Zinc_15987659 L-Name(Control) -96 -61.02 -34.97 -0.05 
5. Zinc_18825330 Genistein -93.6 -75.93 -17.68 0 
6. Zinc_18847037 Biochanin A -93.5 -67.63 -25.86 0 
7. Zinc_8681784 Beta-sitosterol -93.1 -85.96 -7.11 0 
8. Zinc_00153654 Sinapic acid -92.4 -68.35 -19.54 -4.54 
9. Zinc_00021790 Ethyl gallate -88 -52.4 -35.58 0 
10. Zinc_00083315 Tryptophan -87.3 -68.34 -16.25 -2.73 
11. Zinc_18847034 Daidzein -86.7 -74.48 -12.19 0 
12. Zinc_00001504 Gallic acid -86.7 -59.07 -24.64 -3 
13. Zinc-03802189 Linolenic acid -82.7 -70.23 -11.68 0.79 
14. Zinc_14438802 Ascorbic acid -76.6 -55.34 -21.25 0 
15. Zinc_02557133 Sulforaphane -61.8 -54.96 -6.87 0 
 
Table 8: Interaction profiles of phytoconstituents with TNF-α 
S. No. Zn file Compound name Energy(kcal/mol) VDW H-Bond Elec 
1. Zinc_04096693 Sissortin -100.8 -73.02 -27.82 0 
2. Zinc_03869685 Quercitin -95.8 -68.57 -27.2 0 
3. Zinc_03872446 Ellagic Acid -92.1 -58.44 -33.65 0 
4. Zinc_30691736 Apremilast(Control) -91.1 -81.72 -9.38 0 
5. Zinc-03802189 Linolenic acid -90.8 -80.56 -10.64 0.41 
6. Zinc_18847037 Biochanin A -85.8 -70.71 -15.12 0 
7. Zinc_00083315 Tryptophan -85.7 -64.8 -16.99 -3.93 
8. Zinc_18825330 Genistein -85.6 -72.61 -12.98 0 
9. Zinc_00021790 Ethyl gallate -84.5 -45.8 -38.72 0 
10. Zinc_18847034 Daidzein -80.6 -58.94 -21.68 0 
11. Zinc_14438802 Ascorbic acid -78.6 -48.98 -29.67 0 
12. Zinc_8681784 Beta-sitosterol -78 -78.01  0 0 
13. Zinc_00001504 Gallic acid -77 -52.27 -24.74 0 
14. Zinc_00153654 Sinapic acid -73.9 -54.07 -19.82 0 
15. Zinc_02557133 Sulforaphane -62.1 -55.25 -6.82 0 
 
Table 9.1: ADMET predicted profile for active component-absorption (1-14) 
Parameter 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
BBB + + - + + - - + + - + - + + 
Human Intestinal Absorption - + + + + + - + + + + + + + 
Caco-2 Permeability - + + + - - - + + - + - + - 
P-glycoprotein substrate NS  NS NS NS S S NS S NS S NS S  NS  NS 
P-glycoprotein inhibitor NI  NI NI  NI NI NI NI NI NI NI NI NI NI NI 
Renal organic cation transporter NI  NI NI  NI NI NI NI NI NI NI NI NI I NI 
Active components: 1-Ascorbic acid, 2-Beta Sitosterol, 3-BiochaninA, 4-Daidzein,5-Ellagic acid, 6-Ethyl gallate, 7-Gallic acid, 8-Genistein, 9-Linolenic 
acid, 10-Quercitin, 11-Sinapic acid, 12-Sissotrin, 13-Sulforaphane, 14-Tryptophan. 
+: Positive,-: Negative, NS: Nonsubstrate, S: Substrate, NI: Noninhibitor,I: Inhibitor, BBB: Blood-brain barrier, ADMET: Absorption, Distribution, 
Metabolism, and Excretion and Toxicity. 
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Fig. 2: Ramachandran plots of Genes (COX-1, COX-2, TNF-α, IL-1β, iNOS and nNOS) 
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Table 9.2: ADMET predicted profile for active component-Metabolism (1-14) 
Parameter 1  2 3 4 5 6 7 8 9 10 11 12 13 14  
CYP450 2C9 Substrate NS NS NS NS  NS NS NS NS NS NS NS NS NS NS 
CYP450 2D6 Substrate NS NS NS NS  NS NS NS NS NS NS NS NS NS NS 
CYP450 3A4 Substrate NS S NS NS  NS NS  NS NS NS NS NS NS NS NS 
CYP450 1A2 Inhibitor NI NI I I NI NI NI I I NI NI NI NI NI 
CYP450 2C9 Inhibitor NI NI I I NI  NI NI I NI NI NI NI NI NI 
CYP450 2D6 Inhibitor NI NI NI  NI NI NI NI NI NI NI NI NI NI NI 
CYP450 2C19 Inhibitor NI NI I I NI  NI NI I NI NI NI NI NI NI 
CYP450 3A4 Inhibitor NI NI I NI  NI NI NI I NI NI NI NI NI NI 
NS: Non-substrate; NI: Non-Inhibitor; I: Inhibitors; S: Substrate, CYP450: Cytochrome P450  
 
Table 9.3: ADMET predicted profile for active component-Toxicity (1-14) 
Parameter  1 2 3 4  5 6 7 8 9 10 11 12 13 14 
Human Ether-a-go-goRelated 
Gene Inhibition 
WI WI WI WI WI  WI WI WI WI  WI WI WI SI I 
AMES Toxicity NT NT NT NT NT NT NT NT NT NT NT NT  NT NT 
Carcinogens NC NC NC NC NC NC NC NC C NC NC NC  C NC 
Fish Toxicity Tetrahymena LT HT HT HT HT HT HT HT HT HT HT HT  LT HT 
Pyriformis Toxicity LT HT HT HT HT HT HT HT HT HT HT HT  LT HT 
Honey Bee Toxicity HT HT HT HT HT HT HT HT HT HT HT HT  HT HT 
Biodegradation RB NRB NRB NRB  NRB RB RB NRB RB NRB RB NRB NRB RB 
Acute Oral Toxicity IV I III II II III III II III II III III III II 
WI: Weak inhibition, NT: Non-Toxic, NC: Noncarcinogen, C: Carcinogen, HT: High toxic, RB: Readily biodegradable, NRB: Not readily biodegradable, 






Fig. 3: Docking pattern of various phytoconstituents with different proinflammatory genes 
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In silico molecular docking is a useful approach in drug discovery 
and therapeutics employable to neuro inflammatory disorders/ 
diseases. Lipinski's rule of five and ADMET are useful tools in 
detecting the drug-likeness and toxicity of phytoconstituents or 
drugs. These tools predicted the drug-likeness and non-toxicity of 
these compounds making suitable drug candidates based on their 
pharmacokinetic nature.  
The present study was undertaken to evaluate the antineuro-
inflammatory activity of selected phytoconstituents. This is the first 
study in our knowledge to carry out in silico study on multiple 
neuroinflammatory mediators as therapeutic targets of 
phytoconstituents [10-12]. The molecular docking analysis of the 14 
phytoconstituents mined from various plants-performed on 
different proinflammatory mediators such as TNF-α, IL-1β, COX-1, 
COX-2, nNOS and iNOS, using the iGEMDOCK. The phytoconstituent 
sissotrin has come out as the common best putative drug candidate 
against all the neuroinflammatory mediator proteins showing 
highest binding affinity. The phytoconstituents Genistein, quercitin, 
biochanin A, β-sitosterol, shows comparatively less binding affinity. 
The activity of these phytoconstituents can be further analyzed and 
assessed by in vitro and in vivo studies to validate the anti-neuro 
inflammatory nature. 
CONCLUSION 
The Present study indicates that all the 14 phytoconstituents 
following Lipinski's rule of fives and expected to be an active 
component as a drug. The results obtained from the docking studies 
showed that sissotrin has a highest binding affinity with all 
proinflammatory genes. Sissotrin can be utilized to treat various 
neuroinflammatory diseases like AD and PD. ADMET showed the 
molecular properties of the compound which support the fact that it 
becomes a lead drug. As proteins taken for docking are 
proinflammatory mediators involved in neuroinflammation. This in 
silico study is actually an additional advantage to screening the 
proinflammatory mediator’s inhibition. Further research with the 
above compounds and in vivo studies are essential to developing a 
potent drug for the prevention and treatment of neuroinflammatory 
disorders. Therefore, in silico study reveals that sissotrin may act as 
a potent drug against neurological disorders. 
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